Vaccines and seeds are the most significant resources in the poultry industry, particularly for chicken as a global staple. However, designing a resilient network for the poultry vaccine supply chain to create a viable poultry industry has been neglected. Hence, this paper contributes to the...

Cervical cancer, primarily caused by persistent Human Papillomavirus (HPV) infection, remains one of the leading causes of cancer-related deaths among women in developing countries. Although HPV vaccines are widely available in these regions, vaccine uptake remains persistently low. To address...

he authors use county-level data to test whether an array of socioeconomic, demographic, political and religious variables explain COVID-19 vaccination rates. Results presented here build upon previous investigations of COVID-19 vaccine hesitancy in different contexts and are largely consistent...

This paper investigates the effect of herd behavior, or information cascades, on the willingness to be vaccinated against COVID-19. We use the 2021/2022 wave of the European Social Survey combined with data from the organization Our World in Data and measure the herding behavior as the change in...

The COVID-19 pandemic significantly disrupted daily life and exacerbated global inequalities, leading policymakers to seek innovative, evidence-based solutions to mitigate its impacts. By March 2023, the pandemic had resulted in approximately 6.88 million reported deaths and 14.83 million excess...

This paper analyses changes in the speed of labour demand for new hires in response to the lockdowns that were repeatedly put in place to contain the spread of the COVID-19 pandemic. It tests whether the uncertainty-reducing effect of similar lockdowns occurring in quick succession increased the...

In September 2023, ECDC updated its COVID-19 vaccination coverage data analysis process, in view of the evolving timing and objective of the 2023-24 season vaccination campaigns. This report presents a description of COVID-19 vaccine coverage in the European Union/European Economic Area (EU/EEA)...

The 2024 ECDC influenza survey on national vaccination recommendations and coverage used and adapted the previous ECDC-funded survey conducted by the Vaccine European New Integrated Collaboration Effort (VENICE) project. The aim of the survey was to describe the evolution of seasonal influenza...

The overall aim of the study is to monitor near real-time performance of COVID-19 vaccines administered as part of 2023 autumnal vaccination campaigns in the community-dwelling resident population aged ≥65 years in EU/EEA countries to detect any variation in VE, so that public health vaccine...

This core protocol for ECDC studies of VE against hospitalisation with severe acute respiratory infection (SARI) laboratory-confirmed with SARS-CoV-2 or with influenza, version 4.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine...

The COVID-19 vaccines played a pivotal role in safeguarding populations. Yet, vaccine hesitancy remained a significant barrier to increasing coverage rates, as many high-income countries faced prolonged vaccine refusal campaigns. In Japan, vaccine doses were administered under a reservation...

The rising number of refugees and internally displaced people (IDPs) presents new challenges for vaccine distribution and the spread of diseases. How do forcibly displaced population inflows affect infectious diseases incidence in host communities? Can a policy intervention that vaccinates...

This study investigates the relationship between economic preferences and COVID-19 vaccination readiness using two representative samples of the German population (N 5,000). We elicited altruism, patience, risk-taking and trust using validated survey questions. We find robust, positive...

In September 2023, ECDC updated its COVID-19 vaccination coverage data analysis process, in view of the evolving timing and objective of the 2023-24 season vaccination campaigns in the European Union/European Economic Area (EU/EEA). This report presents an interim description of COVID-19 vaccine...

Cervical cancer is the fourth most common cancer affecting women worldwide. It is caused by persistent infection with oncogenic types of human papillomavirus (HPV). More than 200 types of HPV have been identified and more than 40 types of them infect the genital tract. HPV 16 and 18 are the two...

In September 2023, ECDC updated its COVID-19 vaccination coverage data analysis process, in view of the evolving timing and objective of the 2023-24 season vaccination campaigns. This report presents an interim description of COVID-19 vaccine coverage in the European Union/European Economic Area...

With Europe's Beating Cancer Plan, the European Commission is supporting effective cancer strategies that can prevent illness, save lives and reduce the impacts of cancer. This includes a Flagship Initiative to address cancers that can be prevented by vaccination, namely cancers caused by Human...

Seasonal influenza is a respiratory infectious disease that spreads globally through annual epidemics and occasional pandemics. Vaccination is the most effective means for preventing influenza infection. However, the effectiveness of influenza vaccines varies to some degree from season to...

The end of 2019 saw the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). As of October 2023, almost 276 million cases and more than 2.2 million deaths had been reported in the WHO European Region [1]. As of October...

Influenza is a disease of public health importance due to the substantial seasonal morbidity and mortality and the high pandemic potential of its aetiologic agents, influenza viruses. Diagnosis of influenza is mainly based on laboratory testing (i.e. molecular testing) of nasopharyngeal samples....

This protocol describes the common methodology to be applied to established health data registries across seven participating European Union/European Economic Area (EU/EEA) Member States to estimate vaccine effectiveness for Coronavirus disease 2019 (COVID-19) in children and adolescents aged...

This paper examines the local impact of COVID-19 in 2,500 cities in Brazil, contrasting findings with existing international estimates. It shows that pre-pandemic city characteristics have time-varying correlations with COVID-19 deaths per capita in Brazil and that the evolution of these...

This study investigates the relationship between economic preferences and COVID-19 vaccination readiness using two representative samples of the German population (N 5,000). We elicited altruism, patience, risk-taking and trust using validated survey questions. We find robust, positive...

We assess whether the COVID-19 vaccine induces COVID-19 risky behavior (e.g., going to bars and restaurants) and thus reduces vaccine efficacy. A key empirical challenge is the endogeneity bias when comparing risk-taking by vaccination status since people choose whether to get vaccinated. To...

This study presents empirical evidence on the impact of public funding on the vaccination rate of children under one-year-old in Vietnam from 2014 to 2019. The research findings indicate that, first, the effect of government funding on the vaccination rate of children is positive after...

During 2021, most Latin American countries successfully deployed vaccines and their labor markets began to recover from the COVID-19 slump. Using two waves of the 2021 HFPS, we investigate the connection between immunization and employment recovery. We first show the highly uneven social impact...

This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living...

This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries. This work is performed within the Vaccine Effectiveness, Burden and...

The end of 2019 saw the emergence of a novel severe acute respiratory syndrome: coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). As of December 2023, eight vaccines (Comirnaty, Spikevax, Vaxzevria, Jcovden Valneva, Nuvaxovid, VidPrevtyn, and Bimervax) have been...

Using London Stock Exchange data (Jan 10, 2021, to Feb 24, 2022) and fixed-effects regression methods, this study assesses COVID-19 vaccine effects on UK stock returns. Initial protocol doses have a strong positive impact on returns, while boosters have a modest positive impact. A logarithmic...